2025
Citrus pectin-coated inhalable PLGA nanoparticles for treatment of pulmonary fibrosis
Perera K, Ghumman M, Sorkhdini P, Norbrun C, Negash S, Zhou Y, Menon J. Citrus pectin-coated inhalable PLGA nanoparticles for treatment of pulmonary fibrosis. Journal Of Materials Chemistry B 2025, 13: 3325-3339. PMID: 39918485, PMCID: PMC11804936, DOI: 10.1039/d4tb01682c.Peer-Reviewed Original ResearchConceptsAnti-fibrotic therapiesPulmonary fibrosisUpregulated markersGalectin-3Off-target effectsTransforming growth factor-bTreatment of pulmonary fibrosisA-smooth muscle actinBleomycin-induced fibrosisMarkers of fibrosisAnti-fibrotic drugsGrowth factor BDose-dependent mannerNanoparticles' abilityAnti-fibrotic activityFDA-approved therapeuticsInhalable nanocarriersFibrotic lung tissueProfibrotic markersMRC-5 lung fibroblastsTherapeutic efficacyMouse lungMuscle actinPLGA nanoparticlesLung tissue
2022
Ameliorating Fibrosis in Murine and Human Tissues with END55, an Endostatin-Derived Fusion Protein Made in Plants
Mlakar L, Garrett S, Watanabe T, Sanderson M, Nishimoto T, Heywood J, Helke K, Pilewski J, Herzog E, Feghali-Bostwick C. Ameliorating Fibrosis in Murine and Human Tissues with END55, an Endostatin-Derived Fusion Protein Made in Plants. Biomedicines 2022, 10: 2861. PMID: 36359382, PMCID: PMC9687961, DOI: 10.3390/biomedicines10112861.Peer-Reviewed Original ResearchAnti-fibrotic effectsIdiopathic pulmonary fibrosisSystemic sclerosisPulmonary fibrosisLung fibrosisMouse modelSignificant anti-fibrotic effectEffective anti-fibrotic therapiesBleomycin mouse modelLungs of patientsAnti-fibrotic therapiesPrevention of skinSecond mouse modelCollagen XVIII/endostatinGrowth factor-β1Matrix-degrading enzymesLung transplantationSignificant morbidityHuman tissuesLung diseaseHealth burdenEffective treatmentFactor-β1Organ fibrosisFibrosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply